Abstract
Introduction
Replication-incompetent recombinant adenovirus vectors (Adv) have been widely used for gene therapy because of their high transduction efficiency in a broad spectrum of dividing and non-dividing cells in vitro and in vivo. However, it still remains a major problem that immune responses against Adv and its transgene attenuate the safety and efficiency of Adv-based gene therapy (1) . In 1999, a patient with partial ornithine transcarbamylase deficiency died after 4 days of Adv gene therapy. It is speculated that the cause of death was systemic inflammatory response syndrome, which is caused by a dysregulation of innate immunity (2) . The innate immune response to Adv is elicited within a few hours after Adv administration in vivo, resulting in the reduction of gene transduction efficiency in the early stage after Adv administration (3, 4) . Moreover, the innate immune response leads to the induction of an adaptive immune response to Adv, which results in a reduction of gene expression efficiency in the late stage after Adv administration (5) (6) (7) . On the basis of these facts, in order to develop a safer and more effective Adv for gene therapy, it is important to reveal the molecular mechanisms of the immune response to Adv in vivo.
Type I interferons (type I IFNs) are important factors for enhancing innate immunity and eliciting adaptive immunity, and their expression is induced by several pattern-recognition receptors (PRRs). Type I IFNs promote the expression of several cytokines and interferon-stimulating genes (ISGs) and show several antiviral effects, such as suppression of viral replication, enhancement of dendritic cell (DC) function and NK cell activation (8) (9) (10) (11) . Previously, it was reported that type I IFNs produced following Adv administration activate NK cells, resulting in the elimination of Advinfected cells and leading to a reduction of the transgene expression level (12) . Thus, to achieve a highly efficient level of Adv-encoded transgene expression, it is important to prevent NK-cell activation.
The antiviral innate immune response is initiated by the recognition of viral components by PRRs, which are classified into membrane and cytosolic types by their localization within the cell. For example, TLRs are the most representative of the membrane-type PRRs, while the retinoic-acid-inducible gene I (RIG-I)-like receptors, including RIG-I and the nucleotide-binding oligomerization domain-like receptors, are expressed in the cytosol. Alternatively, these receptors are classified by the type of ligands. TLR3 and TLR7/TLR8, the membrane-associated RNA sensors, recognize doublestranded RNA (ds-RNA) and single-stranded RNA (ss-RNA), respectively, and TLR9, the membrane-associated DNA sensors, recognizes unmethylated CpG DNA. On the other hand, a cytosolic RNA sensor including RIG-I, which has an RNA helicase domain, recognizes 5′-triphosphate RNA (13) . In the case of Adv, we and others have reported that Adv genomic DNA was recognized by TLR9 in the endosome (14, 15) . Recently, it has been reported that a cytosolic DNA sensor, cyclic GMP-AMP synthase (cGAS), recognized the genomic DNA of pan-DNA viruses, including Adv (16, 17) . In addition, we previously reported that Adv-derived virus-associated RNAs (VA-RNAs), which are transcribed by RNA polymerase III, were recognized by some RNA sensors and transduced intracellular signaling through an IFN-β promoter stimulator (IPS)-1 (18, 19) . On the other hand, several studies have suggested that Adv capsid proteins activate the innate immune response through inflammasome activation (20, 21) . Thus, although it has been revealed that each component of Adv activates the innate immune response via different mechanisms, the impact of each mechanism on the transgene expression of Adv remains unclear.
To address this issue, we focused on the intracellular signaling induced by nucleic acids. Since TANK-binding kinase 1 (TBK1) is a downstream molecule of cGAS and IPS-1 (17, 22) , it is expected that Tbk1-deficient mice would provide insight into the impact of the innate immune response induced by Adv-derived nucleic acids. In this study, we revealed that the induction of innate immune responses such as type I IFN expression and NK cell activation following Adv administration were regulated by TBK1-dependent or TBK1-independent signaling in the spleen or the liver, respectively. Furthermore, our findings suggested that these differences were defined by the type of cells located in those tissues. Therefore, it was suggested that Adv-derived nucleic acids induce the innate immune response in a cell-type-specific manner.
Methods

Mice
Tbk1
−/− Tnf −/− and Tbk1
Tnf −/− mice (C57BL/6-background) were generated previously (23) . Since Tbk1 −/− mice show embryonic lethality due to the overproduction of TNF-α, Tnfadeficiency is introduced. All mice were housed in an animal facility under specific-pathogen-free conditions and were used at 6-8 weeks of age. All animal experimental procedures used in this study were performed in accordance with the institutional guidelines for animal experiments of Osaka University and the National Institute of Biomedical Innovation.
Preparation and administration of Adv
The adenovirus type 5 vector-expressing LacZ (Ad-LacZ) was previously constructed (24) . Briefly, the expression cassette containing β-actin promoter with the cytomegalovirus enhancer (CA)-driven (25) LacZ gene was inserted into the E1/ E3-deleted adenovirus type 5 genome. This virus was grown in 293 cells by standard techniques. Ad-LacZ was purified with CsCl 2 step-gradient ultra-centrifugation, dialyzed with a solution containing 10 mM Tris (pH 7.5), 1 mM MgCl 2 and 10% glycerol, and stored in aliquots at -80°C. Determination of the virus particle (vp) titers was accomplished spectrophotometrically according to the methods of Maizel et al. (26) . Adv were intravenously administered at 5 × 10 10 vp per mouse.
5-Bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal) staining
The sections of fresh frozen spleen and liver tissue (5 μm) were fixed in 0.5% glutaraldehyde for 10 min, rinsed two times for 10 min with PBS and incubated with 1 mg ml -1 of X-gal, 5 mM K 3 [Fe(CN) 6 ], 5 mM K 4 [Fe(CN) 6 ], 0.01% sodium deoxycholate and 2 mM MgCl 2 in PBS at 37°C. Sections were counterstained with hematoxylin and examined microscopically. The images were analyzed by ImageJ software. The blue area and intensity in a field were calculated as the β-galactosidase (β-gal) intensity.
Isolation of mononuclear cells
Splenocytes were isolated by a standard mechanical disruption procedure, followed by lysis of the red blood cells and then the components were passed through a nylon mesh. Intrahepatic lymphocytes were isolated by a standard procedure. In brief, the liver was homogenized using a plunger and the homogenates were passed through a nylon mesh. The cell suspensions were incubated in PBS containing collagenase type D (Roche, GmbH, Germany) and DNase I (Roche) at 37°C for 45 min. The intrahepatic lymphocytes were then isolated by a discontinuous density gradient procedure (44% and 56%) with Percoll PLUS (GE Healthcare, Tokyo, Japan). The cells that were layered between the 44% and 56% interface were collected as intrahepatic mononuclear cells.
Flow cytometry
APC-conjugated anti-NK-1.1, Pacific Blue-conjugated anti-CD69, Biotin-conjugated CD11b and Brilliant Violet 421-conjugated streptavidin were purchased from BioLegend (San Diego, CA, USA). PE-Cy7-conjugated anti-CD3ε and APC-conjugated anti-CD11c were purchased from eBioscience (San Diego, CA, USA). PE/Cy7-conjugated CD45 was purchased from BD Biosciences (San Jose, CA, USA). Samples were acquired by an LSR Fortessa flow cytometer and analyzed using BD FACSDiva™ Ver 6.1.3 software (BD Bioscience) or FlowJo software (TreeStar Inc., Ashland, OR, USA).
Quantitative RT-PCR
Total RNA was isolated from each tissue and cell with ISOGEN reagent (Nippon Gene Tokyo, Japan). Reverse transcription was performed with the SuperScript VILO (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The synthesized cDNA was used as a template for quantitative RT-PCR (qRT-PCR) with SYBR Premix Ex Taq TM II (TaKaRa, Shiga, Japan) and each gene-specific primer: Ifna forward, 5′-CTTCCA CAGGATCACTGTGTACCT-3′; Ifna reverse, 5′-TTCTGCTCTGA CCACCTCCC-3′; Ifnb forward, 5′-CTGGAGCAGCTG AATGGAAAG-3′; Ifnb reverse, 5′-CTTCTCCGTCATCTCCA TAGGG-3′; Ifng forward, 5′-TTTTCCTGGGCATTGTGGTC-3′; Ifng reverse, 5′-GGCATGTCATCCAGGAGGTT-3′; Il6 forward, 5′-CTGCAAGAGACTTCCATCCAG-3′; Il6 reverse, 5′-AGTGGT ATAGACAGGTCTGTTGG-3′; Il12b forward, 5′-CTCAGAAGCT AACCATCTCCTGG-3'; Il12b reverse, 5′-CACAGGTGAGG TTCACTGTTTC-3′; Il15 forward, 5′-ACATCCATCTCGTGCT ACTTGT-3′; Il15 reverse, 5′-GCCTCTGTTTTAGGGAGACCT-3′; Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) forward, 5′-CAATGTGTCCGTCGTGGATCT-3′; Gapdh reverse, 5′-GTCCTCAGTGTAGCCCAAGATG-3′. PCR and analysis were performed on an Applied Biosystems StepOne Plus Real-time PCR system (Life Technologies, Grand Island, NY, USA). Relative expression was calculated using the ΔΔC T method, and the mRNA levels of each gene were normalized by those of Gapdh.
FACS-Gal staining
The activity of β-gal was measured by flow cytometry as previously described (27) . Briefly, isolated mononuclear cells were stained with 1 mM fluorescein di-β-d galactopyranoside (FDG) at 37°C for exactly 1 min. FDG-loaded cells were kept on ice for 1.5 h to allow accumulation of FITC release from FDG in β-gal + cells. Then, the cells were washed and stained with antibody for flow cytometry. Tnf −/− mouse embryonic fibroblasts (MEFs) were prepared from embryos on C57BL/6 backgrounds derived at 13.5 days post-coitum. The MEFs were maintained in DMEM supplemented with 10% FCS and penicillin-streptomycin. Bone marrow cells were cultured in RPMI 1640 medium supplemented with 10% FCS, 100 mM 2-mercaptoethanol and 20 ng ml -1 murine GM-CSF (PeproTech, Rocky Hill, NJ, USA) for 8 days to use as GM-CSF-induced DCs (GM-DCs). MEFs and GM-DCs were infected with Adv.
In vitro Adv infection
Quantitative PCR analysis of Adv genome copy numbers
Total DNA was isolated from GM-DCs and MEFs using a DNeasy Blood & Tissue Kit (QIAGEN, Hilden, DE, USA). The copy numbers of Adv genomic DNA in each cell were quantified with SYBR Premix Ex Taq TM II (TaKaRa) and each gene-specific primer: Ad-E4 forward, 5′-GGGATCGTCTACCTCCTTTTGA-3′; Ad-E4 reverse, 5′-GGGCAGCAGCGGATGAT-3′; Gapdh forward, 5′-CAATGTGTCCGTCGTGGATCT-3′; Gapdh reverse, 5′-GTCCTCAGTGTAGCCCAAGATG-3′. PCR and analysis were performed on an Applied Biosystems StepOne Plus Real-time PCR system (Life Technologies). The copy numbers of adenovirus genomic DNA were normalized by those of Gapdh.
Statistics
Results are shown as the mean ± SEM or ± SD. Statistical significance was analyzed by Student's t-test between two groups or one-way ANOVA among more than three groups (*P < 0.05, **P < 0.01, # P < 0.005, ## P < 0.001).
Results
TBK1 signaling inhibits the transgene expression of Adv in the spleen
Innate immune responses such as degradation of the viral genome and elimination of virus-infected cells are activated within a few hours after viral infection. To identify the role of TBK1 in the innate immune response following Adv administration, Adv were administered to Tbk1-deficient mice. It has been shown that, following intravenous Adv administration, more than 90% of Adv accumulate in the liver, with the remainder mostly accumulating in the spleen, where the immune responses are initiated (28) . To reveal the role of TBK1 in the transgene expression of Adv, LacZ-expressing Adv (Ad-LacZ) were administered into Tbk1 −/− Tnf −/− (Tbk1 −/− ) mice and Tbk1 +/− Tnf −/− (Tnf −/− ) mice as a control, and β-gal expression in the spleen and liver were measured. In the spleen, β-gal expression of Tbk1 −/− mice was higher than that of Tnf −/− mice ( Fig. 1A and B) . On the other hand, there was no difference in β-gal expression in the liver between Tnf −/− mice and Tbk1 −/− mice ( Fig. 1C and D) . Together, these results suggest that TBK1-dependent signaling in the spleen inhibits transgene expression of Adv, but not in the liver. 
TBK1 in Adv-induced innate immunity 107
NK cells are activated via TBK1 signaling in the spleen following Adv administration
Previous studies have shown that NK cells played an important role in the elimination of Adv-infected cells, resulting in a decrease of transgene expression (12) . To elucidate the reason why β-gal expression was increased in the spleen of Tbk1 −/− mice, we examined whether NK-cell activation following Adv administration is dependent on TBK1 signaling. Two days after the Adv administration, we estimated the activation status of tissue-resident NK cells. In Tbk1 −/− mice, the proportion and number of total NK cells in the spleen were significantly decreased compared with those in Tnf −/− mice ( Fig. 2A) , whereas the number in the liver was increased (Fig. 2B) . The expression of CD69, which is one of the activation marker of NK cells, was up-regulated in both the spleen and liver of Tnf −/− mice (Fig. 3) . Interestingly, the proportion and number of CD69 + NK cells in the spleen were also decreased in Adv-administrated Tbk1 −/− mice compared with those in Tnf −/− mice (Fig. 3A) , whereas the number of CD69 + NK cells in the liver of Tbk1 −/− mice was comparable with that in Tnf −/− mice (Fig. 3B) . These results indicate that NK cells following Adv administration proliferated via TBK1 signaling in the spleen, but not in the liver. Thus, it is suggested that following Adv administration, TBK1-dependent signaling promotes the proliferation of NK cells in the spleen, which eliminates transgene-expressing cells, whereas NK cells in the liver proliferate via TBK1-independent signaling. The innate immune response induced by Adv in the spleen could therefore be controlled by a different mechanism than that in the liver.
TBK1 signaling is required for the expression of type I IFNs and inflammatory cytokines in the spleen
The activation of NK cells is regulated by type I IFNs, whereas their homeostatic expansion is regulated by IL-15 (12, 29) . To reveal the mechanism of NK-cell activation via (Fig. 4B) . Consistent with the number of activated NK cells, the expression of Ifng, which is presumably expressed mainly in NK cells rather than other cell types, was decreased in the spleen but not in the liver of Adv-administered Tbk1 −/− mice. There was no significant difference in Il15 expression in either the spleen or the liver between Tnf −/− mice and Tbk1 −/− mice, supporting the notion that the number of total NK cells at steady state was similar between them. These results indicate that type I IFNs and inflammatory cytokines were expressed via TBK1-dependent signaling in the spleen following the Adv administration, whereas they were up-regulated via TBK1-independent signaling in the liver. Thus, it was suggested that this difference in the expression of type I IFNs was responsible for the difference in the activation of NK cells between the spleen and the liver.
TBK1 signaling is required for the expression of type I IFNs and inflammatory cytokines in immune cells
In a previous report, Adv were found to elicit an innate immune response through several pathways in a cell-typespecific manner (14, 30) . In the present study, histological analyses (Fig. 1A) suggested that Adv were efficiently transduced into immune cells such as DCs and macrophages in the marginal zone of the spleen, which was consistent with a previous report (31) . To identify the Adv-infected immune cells, we first measured the activity of β-gal in the splenic and liver immune cells by FACS-Gal staining. Although splenocytes exhibited higher endogenous β-gal activity, it was revealed that CD11b +
CD11c
+ cells with high β-gal activity existed in both Tnf −/− mice and Tbk1 −/− mice (Fig. 5A ). On the other hand, approximately 95% of immune cells (CD45 + cells) exhibited β-gal activity in the liver of Tnf −/− mice, whereas CD45 + cells exhibited much lower β-gal activity in the liver of Tbk1 −/− mice (Fig. 5B) . 
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Adv were previously shown to efficiently infect non-immune cells such as hepatocytes in the liver (28) . In the present study, it was revealed that Adv-infected cells in the spleen are mainly CD11b + CD11c + cells. We therefore hypothesized that the difference in the expression patterns of cytokines between the spleen and the liver was due to the difference in the type of Adv-infected cells. To test this hypothesis, we examined the cytokine expression patterns of GM-CSF-induced bonemarrow-derived DCs (GM-DCs) as immune cells and MEFs as non-immune cells by Adv infection. The results showed that, whereas Adv induced the expression of type I IFNs and inflammatory cytokines in Tnf −/− GM-DCs, the induction was much lower in Tbk1 −/− GM-DCs (Fig. 6A) . On the other hand, Adv induced the expression of type I IFNs and inflammatory cytokines in MEFs despite their lacking expression of TBK1 (Fig. 6B ). In addition, there were no significant differences in the number of infected Adv between Tnf −/− cells and Tbk1 −/− cells (Fig. 6C) , suggesting that the impaired expression of type I IFNs and inflammatory cytokines in Tbk1 −/− GM-DCs was not due to a low efficiency of Adv infection. These results lead us to propose that TBK1 signaling is dominant in immune cells, but not in non-immune cells.
Discussion
Although Adv are among the most promising vectors for gene therapy, the rapid induction of innate immune responses by Adv, such as inflammatory cytokine production and subsequent tissue damage, attenuates their transduction efficiency. Previously, it has been demonstrated that various components of Adv, such as capsid proteins, genomic DNA and VA-RNA, induced innate immunity (14-16, 18, 19, 32) . However, it is still unclear which Adv component induces the innate immune response in vivo. In order to identify the component, we focused on the intracellular signaling of nucleic acid sensing. TBK1 associates with IPS-1 and the stimulator of interferon genes, which are adaptor molecules for RNA sensors and DNA sensors, respectively, and promotes type I IFN expression through the activation of interferon regulatory factors (IRFs) (33) . On the other hand, it has been reported that TBK1 is also associated with TIR domain-containing adapter-inducing IFN-β, which is an adaptor molecule for TLR3 and TLR4 (34) (35) (36) . Given that Adv is a DNA virus, TLR3, an endosomal sensor for ds-RNA, should not be involved in the Adv-induced innate immune response. Doronin et al. 110 TBK1 in Adv-induced innate immunity (37) suggested that a mutant adenovirus that failed to bind coagulation factor X lacked the ability to bind to TLR4, which induced a level of type I IFNs comparable to that induced by the wild-type adenovirus. On the basis of these previous observations, Tbk1-deficient mice were expected to provide insight into the importance of the nucleic acids sensor in the innate immune responses induced by Adv.
To investigate the role of TBK1 in the innate immunity against Adv, we used mice lacking both TBK1 and TNF-α. Since Tbk1-deficiency caused overproduction of TNF-α, which results in embryonic lethality, Tnfa-deficiency was introduced into Tbk1-deficient mice. We examined differences in cytokine expression levels in both the spleen and the liver between wild-type mice and Tnf −/− mice. The results suggested that the induction of innate immunity was not largely affected by the Tnfa-deficiency in the present study, because the effects of Tnfa-deficiency on the expression of most cytokines after Adv administration were less pronounced than the effects of Tbk1-deficiency (Supplementary Figure 1 , available at International Immunology Online). We previously reported that Adv fail to induce the production of TNF-α in DCs (38) , which might support the data in vivo in Supplementary Figure 1 , available at International Immunology Online. The effect of Tnfa-deficiency in DCs would be negligible. Taken together, these results suggested that Tnfa-deficiency did not affect the function of TBK1 following Adv administration.
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In the present study, we found that NK-cell activation by Adv was dependent or independent on TBK1 signaling in the spleen or in the liver, respectively (Figs 2 and 3) . This difference in NK-cell activation would be due to the different expression levels of type I IFNs in each tissue and would lead to the distinct levels of Adv transgene expression in the spleen between Tbk1-sufficient mice and Tbk1-deficient mice. On the other hand, type I IFN expression and the number of activated NK cells in the liver of Tbk1-deficient mice were comparable with those of Tbk1-sufficient mice. These results suggest that type I IFN expression is regulated by TBK1-independent signaling and that TBK1 is dispensable for the activation of NK cells in the liver.
Quantitative analyses of the mRNA expression levels of cytokines revealed TBK1-dependency in the spleen and in the liver after Adv administration (Fig. 4) . In the spleen, the expression of type I IFNs was dependent on TBK1 signaling, whereas the expression of IL-6 and IL-12β was partially dependent on TBK1. On the basis of these findings, it was suggested that Adv-derived nucleic acids induce the expression of the type I IFNs, IL-6 and IL-12β, through TBK1 signaling, and that capsid proteins may induce the expression of IL-6 and IL-12β in the spleen. On the other hand, in the liver, the expression of cytokines was independent of TBK1 signaling, suggesting that capsid proteins are required for the induction of innate immunity. Furthermore, the expression of various cytokines, except Ifnb, was up-regulated in the liver of Tbk1-deficient mice, regardless of whether Adv were administered, suggesting that TBK1 suppresses the expression of these cytokines in the liver. Clark et al. (39) demonstrated that TBK1 inhibits IκB kinase (IKK) α/IKKβ phosphorylation, resulting in impaired NF-κB activation. Thus, it is speculated that the expressions of IL-6 and IL-12β were higher in the liver of Tbk1-deficient mice by NF-κB activation. Negishi et al. (40) reported that IRF3, a downstream molecule of TBK1, directly represses Il12b expression, suggesting that a similar repression mechanism might be at play in the liver. FACS-Gal staining, which is more sensitive than X-gal staining (41) , revealed that most immune cells were infected by Adv in the liver of Tbk1-sufficient mice. Moreover, β-gal activity in Tbk1-deficient immune cells in the liver was much lower than that in Tbk1-sufficient immune cells. In the Tbk1-deficient liver, elevated type I IFN expression would be expected to elicit the up-regulation of ISGs, which are known to influence the viral vector-mediated transgene expression (42) . Although the exact reason for the lower β-gal activity in Tbk1-deficient immune cells is not known, it is speculated that the β-gal expression was reduced due to the upregulation of ISGs in Tbk1-deficienct immune cells in the liver. Also, our results showed that CD11b + CD11c
+ cells with high β-gal activity existed in the spleen (Fig. 5A) . Given that CD11b To explore the differences between the spleen and the liver, we examined the innate immune responses in immune cells and non-immune cells (Fig. 6) . It was observed that 
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type I IFNs were up-regulated via TBK1-dependent signaling and that IL-6 and IL-12β were up-regulated via TBK1-dependent and TBK1-independent signaling in the GM-DCs after Adv infection. We previously reported that IL-6 and IL-12β expression are dependent on TLR9/MyD88 signaling in GM-DCs, whereas type I IFN expression is independent of TLR9/MyD88 signaling (14) . Also, type I IFN expression was likely to be independent of IPS-1 signaling, which is essential for the induction of type I IFNs following cytosolic RNA sensing (19) . Therefore, it is suggested that type I IFNs are regulated by Adv-derived nucleic acids via both TBK1-dependent and IPS-1-independent signaling in GM-DCs, presumably due to cytosolic genomic DNA of Adv being sensed by cGAS. Consistent with our hypothesis, Fejer et al. (44) showed that adenoviruses in cytosol induce type I IFN production from GM-DCs in a type I IFN signal-dependent manner. We previously reported that the expression of type I IFNs by Adv was dependent on IPS-1 signaling in MEFs (19) . However, in this study, type I IFN expressions were not decreased in Tbk1-deficient MEFs, in spite of the fact that TBK1 was associated with IPS-1. It is possible that some form of TBK1-independent IPS-1 signaling, presumably NF-κB signaling, compensates for type I IFN expression in Tbk1-deficient MEFs.
Finally, to determine the innate immune response after Adv administration in the whole body, we measured the serum levels of IFN-α and IL-12β. Our measurements in mice showed partially reduced levels of type I IFNs in the serum after Adv administration, compared with wild-type mice (15) . These results indicated that Adv induce the type I IFNs in vivo via both TLR9/MyD88-dependent and TLR9/ MyD88-independent signaling. Therefore, it is suggested that the increase in the IFN-α level in the serum would be induced by endosomal sensing of adenoviral genomic DNA (TLR9/MyD88-dependent) and cytosolic sensing of adenoviral nucleic acids (TBK1-dependent). In summary, we have shown that the Adv-induced immune response is regulated by TBK1-dependent or TBK1-independent signaling in immune cells or non-immune cells, respectively. These results should provide new insights into the molecular mechanisms underlying the role of Adv-derived nucleic acids in the innate immune response. Therapeutic strategies that attenuate or entirely inhibit activation of the innate immune response would help to improve the safety and efficacy of Adv.
Supplementary data
Supplementary data are available at International Immunology Online.
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